FindTrial
Sign In

A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer *ART DECO*

A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer *ART DECO* - ART DECO

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON41614
Enrollment
260
Registered
2012-02-20
Start date
2012-09-28
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagus cancer Oesophageal cancer

Interventions

Radiation dose escalation to the primary tumor. Arm I: standard dose of 50.4 Gy plus concurrent carboplatin and paclitaxel Arm II: as arm I plus a concomitant daily concomitant boost dose of 0.4 Gy t

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: T1-4, N0-3, M0 adeno- or squamous cell carcinoma of the esophagus or esophageal gastric junction referred for definitive chemoradiation

Exclusion criteria

Exclusion criteria: tumors > 10 cm, unfit for definitive chemoradiation, pathologic lymphnodes at both truncus coeliacus and supraclavicular level, esophageal stent in situ.

Design outcomes

Primary

MeasureTime frame
local tumor control—

Secondary

MeasureTime frame
survival, toxicity—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)